Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome and secretome characterization of penile carcinoma cells

ABSTRACT: Representing a rare malignant disease, penile cancer (PeCa) occurs in 0.4 - 0.6 % of male neoplasias in Europe and the USA. With more than 95 %, most PeCa are of squamous cell origin and can be further distinguished based on their HPV-status. This study aimed at elucidating the secretome and proteome of newly established PeCa cell lines to identify biomarker and putative therapeutic targets, respectively.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Malignant Cell, Cell Culture

DISEASE(S): Penile Cancer

SUBMITTER: Gereon Poschmann

LAB HEAD: Gereon Poschmann

PROVIDER: PXD071333 | Pride | 2026-04-06

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	LM08563.mzML	Mzml
	LM08563.mzTab	Mztab
	LM08563.raw	Raw
	LM08564.raw	Raw
	LM08565.raw	Raw

Items per page:

1 - 5 of 12

Publications

Targeting histone deacetylation, cell cycle regulators and heat shock proteins as novel therapeutic strategies for penile cancers.

Marson Lara L Skowron Margaretha A MA Pongratanakul Pailin P Kotthoff Mara M Poschmann Gereon G Bohnenberger Hanibal H Stephan Alexa A Watolla Meike M MM Mukinovic Elvira E Stühler Kai K Kurz Thomas T Ayoubian Hiresh H Linxweiler Johannes J Junker Kerstin K Nettersheim Daniel D

NPJ precision oncology 20260331 1

Penile carcinoma (PeCa) is a rare malignancy occurring in men. Treatment typically involves penectomy, radiation, or cisplatin-based chemotherapy. A paclitaxel, ifosfamide, and cisplatin-based regimen achieves response rates around 65%. However, non-responders face a 5-year survival rate of only 8%, and due to its rarity, it is mediocrely characterized. Thus, an in-depth delineation of PeCa is crucial to identify novel therapeutic targets. Newly established primary human PeCa cell lines and corr ...[more]

PMID: 41917338

Similar Datasets

The proteome of human amyloid beta oligomers

Project description:Amyloid β (Aβ) oligomers are thought to play an important role in the onset and progression of Alzheimer’s disease (AD). Several oligomer-binding proteins have been implicated in mechanisms leading to AD pathology. Such proteins could provide insights into the pathways involved in the disease process of AD and might reveal novel targets for disease-modifying therapy approaches. Here, we separated different native Aβ assemblies in brain homogenates of human AD post mortem tissue by density gradient centrifugation, then isolated Aβ-containing complexes by co-immunoprecipitation. Mass spectrometry of immunoprecipitated proteins with label-free quantification (LFQ) showed numerous significant changes between AD and control samples, confirming familiar binding proteins and also indicating putative new interactors.

2026-04-07 | PXD053759 | Pride

Proteomic profiling of CLDN6-deficient germ cell tumor cells

Project description:Representing a crucial factor during cell adhesion, polarity, proliferation and migration, the transmembrane protein claudin 6 (CLDN6) has been shown to be a putative target for the treatment of germ cell tumors (GCT). Particularly seminoma (SE), embryonal carcinoma (EC), and choriocarcinoma (CC) indicated high CLDN6 levels, while about 60 % of yolk-sac tumors (YST) presented as CLDN6+. In this study, we generated CLDN6-deficient GCT cells by CRISPR/Cas9 for SE, EC, and CC cells, while YST cells were cell sorted for CLDN6+ and CLDN6- populations. Further, the putative function of CLDN6 was investigated on proteome level using liquid-chromatography coupled with mass spectrometry (LS-MS).

2026-04-07 | PXD066158 | Pride

Characterization of cancer-associated fibroblasts from ex vivo germ cell tumors

Project description:Cancer-associated fibroblasts (CAF) as one abundant cell type of the tumor microenvironment are known to have tumor supporting abilities by promoting tumor proliferation and modulating the immunal landscape. In this study, germ cell tumor-derived CAF were molecular and epigenetically characterized to identify CAF secreted signal molecules which play a pivotal role in the GCT-CAF interaction.

2024-11-15 | PXD049249 | Pride

Identification of factors secreted by testicular germ cell tumor cell lines and microenvironmental cells.

Project description:Type II germ cell tumors (GCTs) are the most common neoplasia in young men of age 14-45 years. It is generally accepted that GCTs arise from a common precursor lesion, called germ cell neoplasia in situ (GCNIS), eventually developing into seminomas or non-seminomas, such as (embryonal carcinomas, ECs). The latter stem-cell like EC can further differentiate into teratomas (TE), yolk-sac tumors (YST), or choriocarcinomas (CC). Even though cisplatin-based chemotherapy is an efficacious standard of care during the management of GCT patients, the development of cisplatin resistance remains a major obstacle. As such, the surrounding tumor microenvironment and its secreted factors could endorse the development of drug resistance. These stromal cells, including immune cells (e.g. macrophages, T-lymphocytes), endothelial cells, and fibroblasts, can influence tumor cells by promoting proliferative and anti-apoptotic signaling pathways. Vice versa, microenvironmental cells can be influenced by tumor cells as well. For the identification of secreted proteins, cell lysates and supernatants from seven human germ cell tumor cell lines (seminoma: TCam-2; embryonal carcinoma (EC): 2102EP, NCCIT; choriocarcinoma (CC): JAR, JEG-3), yolk-sac tumor (YST): GCT72; 1411H) and five human cell types from the microenvironment (fibroblasts: MPAF, HVHF2; M2 macrophages: THP-1-M2; T-lymphocytes: JURKAT; endothelial cells: HUVEC) have been evaluated using liquid chromatography coupled with mass spectrometry (LC-MS).

2022-10-13 | PXD031329 | Pride

The Golgi stacking protein GRASP55 represents an effector protein of the natural compound Prodigiosin

Project description:The bacterial secondary metabolite prodigiosin has been shown to exert anticancer, antimalarial, antibacterial and immunomodulatory properties. With regard to cancer, it has been reported that it affects tumor cells but not non-malignant cells, making it a promising lead compound for anticancer drug discovery. However, a direct protein target has not yet been experimentally identified. Here, we identify the Golgi stacking protein GRASP55 as effector target protein of prodigiosin and found evidence that GRASP55 knockout cells show an altered pattern on secreted proteins upon prodigionsin treatment.

2023-10-24 | PXD042909 | Pride

Comparative analysis of CVF proteome composition during neoplastic transformation of cervix among females of reproductive age

Project description:The aim of this study is characterization of proteomic composition of the CVF for assessing the severity of HPV-associated intraepithelial neoplasias of the cervix among women of reproductive age.

2021-11-15 | PXD011472 | Pride

Whole-genome shallow-sequencing of HPV-positive and HPV-negative vulvar lesions

Project description:Identification of copy number alterations of HPV-positive and HPV-negative vulvar squamous cell carcinomas (VSCC) and vulvar intraepithelial neoplasias (VIN), with special focus on VIN with and without VSCC, the latter group being defined as VIN with no VSCC development during >10 year follow-up.

2018-07-01 | E-MTAB-6113 | biostudies-arrayexpress

Copy number Analysis of Head and Neck cancer cases from two high incidence regions

Project description:The principal objective of this work was to investigate the somatic copy number changes that influence the risk of head and neck cancer occurrence and outcome from two large comprehensive case series in Europe and South America. A second objective was to investigate how these somatic changes interact with environmental and host risk factors such including HPV infection, alcohol and smoking.

2016-06-14 | E-MTAB-4863 | biostudies-arrayexpress

NSD2 is upregulated by high-risk HPV E6/E7 and modulates epithelial differentiation in HPV-associated Head and Neck Cancer

Project description:Epigenetic alterations are a key hallmark of cancer and are increasingly recognized as promising clinical biomarkers and therapeutic targets. Head and Neck Squamous Cell Carcinomas (HNSCC) are classified into two subtypes: HPV-positive (HPV+), driven by human papillomavirus (HPV) infections, and the HPV-negative (HPV-), associated with environmental risk factors. Although exhibiting distinct molecular and clinicopathological features, both subtypes lack effective, tailored therapies. Profiling their epigenetic landscape could thus have important clinical implications. In this study, we employed a quantitative mass spectrometry approach to profile histone post-translational modification (hPTMs) in HPV+ and HPV- HNSCC.

2026-02-20 | PXD064152 | Pride

Expression data from cells located at the invasive front and in the tumor mass of mouse cervical squamous cell carcinomas

Project description:Cells located at the invasive front and in the tumor mass of mouse cervical squamous cell carcinomas were isolated by laser microdissection from hematoxylin-stained HPV/E2 sections. 7 months old HPV/E2 mice treated with oestrogen develop invasive cervical squamous cell carcinomas. This model recapitulates human invasive cervical neoplasias. We used microarrays to compare the transcriptome of cells located at the invasive front versus cells located in the tumor mass of mouse squamous cell carcinomas.

2018-02-01 | GSE108208 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data